Life Science Leader Magazine Supplements

CMO 2017

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link:

Contents of this Issue


Page 50 of 81

K E Y W W W.C M O L E A D E R S H I PA W A R D S .C O M LIFESCIENCELEADER.COM THE CMO LEADERSHIP AWARDS 2017 49 CAPABILITIES COMPATIBILITY DEVELOPMENT EXPERTISE RELIABILITY QUALITY 2017 CMO LEADERSHIP AWARDS WINNERS Company Profiles DRUG LIFE CYCLE STAGES: Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics SERVICES & CAPABILITIES: capsules, cytotoxic & high potency compounds, parenterals: small volume, solid dose, solutions & suspensions, sustained release "We pride ourselves on our ability to not only meet, but exceed expectations to our global clients by ensuring that we provide exceptional and reliable quality in all aspects of our work. Eclipsing that quality determines the extent of our commitment and success." DRUG TYPE: Pharmaceuticals, Biopharmaceuticals ALAN ARMSTRONG Chairman & CEO CATEGORIES WON: Almac Craigavon, Co. Armagh, UK Phone: +44 (0) 28 3833 2200 Contact: Ruth Fowler Email: Key locations: Craigavon, UK; Audubon; Charnwood INDIVIDUAL ATTRIBUTE AWARDS: reputation DRUG LIFE CYCLE STAGES: Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3) Drug Substance Production: Primary Process Development Drug Substance Production SERVICES & CAPABILITIES: aseptic fill/finish, injectables, liquids, lyophilized products, paren- terals: large volume, parenterals: small volume, peptides, proteins, solutions & suspensions, ster- ile, sustained release, syringes: pre-filled, vaccines "Althea's business has grown — a lot — in the past several years. The number of commercial products and countries from which we have received regulatory approval continues to rapidly increase. We are very proud of the growth we have achieved while strengthening our stellar regulato- ry track record. Our technical teams demonstrate a relentless dedication to our clients, each other, and to the patients we all serve. Thank you for validating all of our efforts." DRUG TYPE: Pharmaceuticals, Biopharmaceuticals DAVID ENLOE President & CEO CATEGORIES WON: Ajinomoto Althea San Diego, CA Phone: +1 858 882 0123 Contact: Anish Parikh Email: Key locations: San Diego, CA DRUG LIFE CYCLE STAGES: Research & Development: Clinical (Phase 1, Phase 2, Phase 3) "AMPAC Fine Chemicals is experiencing dynamic growth in business and facilities expansion as we continue to maintain a leadership position in large scale commercial production. As we expand, our heritage of successfully transitioning drugs from development to commercial success remains our core strength. AFC takes pride in being recognized by the pharmaceutical industry as a leader in six categories and believes this reflects our commitment to enabling the success of our customers, large and small." DRUG TYPE: Pharmaceuticals ASLAM MALIK President & CEO CATEGORIES WON: AMPAC Fine Chemicals Rancho Cordova, CA Phone: +1 888 330 2232 Contact: Patrick Park Email: Key locations: Rancho Cordova, CA; La Porte, TX; Petersburg, VA INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on- time, reputation, right first time, state-of-the-art, strength of science SERVICES & CAPABILITIES: analytical testing, APIs and HPAPIs, controlled substances, cytotoxic & high potency compounds, drug substance, fine chemicals, generics, peptides, product stability & release, registered intermediates

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine Supplements - CMO 2017